To hear about similar clinical trials, please enter your email below
Trial Title:
BRAF V600E Mutations In Papillary Thyroid Carcinoma
NCT ID:
NCT01417442
Condition:
Papillary Thyroid Carcinoma
Conditions: Official terms:
Carcinoma
Thyroid Neoplasms
Thyroid Cancer, Papillary
Thyroid Diseases
Conditions: Keywords:
papillary thyroid carcinoma
BRAF V600E
poor prognosis
aggressive
Study type:
Interventional
Study phase:
Early Phase 1
Overall status:
Unknown status
Study design:
Allocation:
Non-Randomized
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Genetic
Intervention name:
BRAF V600E POSITIVITY
Description:
BRAF V600E mutation analysis will be made using the tumor tissues of the patients with
papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation
positives and negatives will be identified.
Arm group label:
BRAF V600E POSITIVITY
Summary:
The purpose of this study is to determine whether BRAF V600E mutation in our patients
with papillary thyroid cancer has an association with poor prognosis.
Detailed description:
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF
V600E mutation is the most common genetic alteration identified in PTC, ranging from 25
to 80%, with the average rate about 45%. Various studies demonstrated a relationship
between BRAF V600E mutation and aggressive characteristics of the cancer, including the
worse patient prognosis. But,there are no studies from Turkey regarding this topic. So
the investigators will examine BRAF V600E mutation in our patients with PTC and try to
assess the role of this mutation in prognosis and further management of the patients.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patients with papillary thyroid cancer
Exclusion Criteria:
- Patients who do not want to be a part of this study
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Yeliz Emine Ersoy
Address:
City:
Istanbul
Zip:
34308
Country:
Turkey
Status:
Recruiting
Contact:
Last name:
Yeliz E Ersoy, DR
Phone:
+905326102713
Email:
yelizemineersoy@yahoo.com
Investigator:
Last name:
Yeliz E Ersoy, M.D.
Email:
Principal Investigator
Start date:
July 2011
Completion date:
July 2012
Lead sponsor:
Agency:
Bezmialem Vakif University
Agency class:
Other
Source:
Bezmialem Vakif University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01417442
